Diagnostic Proves Successful in Phase III Cancer Trial

Neoprobe’s Lymphoseek had a 97 percent success rate in a Phase III clinical trial designed to measure its accuracy in identifying lymphatic tissue, according to a presentation by the researchers in the breast cancer arm of the trial. The trial evaluated 130 patients — 60 with breast cancer and 70 with melanoma. Lymphoseek identified 210 of 215 lymph nodes also identified by commonly used vital blue dye, as well as 85 lymph nodes not found by the dye. Eighteen percent of the lymph nodes found only by Lymphoseek contained tumor, a company statement says.